-
公开(公告)号：US20130197199A1
公开(公告)日：2013-08-01
申请号：US13876763
申请日：2011-09-28
IPC分类号： C07K16/28
CPC分类号： C07K16/28 , C07K16/2869 , C07K17/00 , C07K2317/24 , C07K2317/76 , G01N33/88
摘要： It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.
摘要翻译： 本发明的目的是提供结合人PGE2受体亚型EP4并抑制EP4的功能的抗体或其功能性片段。 本发明的另一个目的是提供一种包含上述抗体或其功能片段的药物。 用人PGE2受体亚型EP4免疫小鼠，并筛选抑制EP4诱导的细胞内cAMP水平升高的单克隆抗体。 另外，测定得到的单克隆抗体的CDR序列。
-
公开(公告)号：US09175080B2
公开(公告)日：2015-11-03
申请号：US13876763
申请日：2011-09-28
IPC分类号： A61K39/395 , C07K16/28 , C07K17/00 , G01N33/88
CPC分类号： C07K16/28 , C07K16/2869 , C07K17/00 , C07K2317/24 , C07K2317/76 , G01N33/88
摘要： It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.
摘要翻译： 本发明的目的是提供结合人PGE2受体亚型EP4并抑制EP4的功能的抗体或其功能性片段。 本发明的另一个目的是提供一种包含上述抗体或其功能片段的药物。 用人PGE2受体亚型EP4免疫小鼠，并筛选抑制EP4诱导的细胞内cAMP水平升高的单克隆抗体。 另外，测定得到的单克隆抗体的CDR序列。
-
3.发明授权Anti-human CCR7 antibody, hybridoma, nucleic acid, vector, cell, pharmaceutical composition, and antibody-immobilized carrier 有权抗人CCR7抗体，杂交瘤，核酸，载体，细胞，药物组合物和抗体固定载体公开(公告)号：US08865170B2
公开(公告)日：2014-10-21
申请号：US13876265
申请日：2011-09-27
申请人： Naoki Nishiguchi , Akiyoshi Hirayama , Masahiro Furutani , Tatsuo Shimizu , Kiyoshi Takayama , Tomoko Shimizu , Kazuya Suzuki
发明人： Naoki Nishiguchi , Akiyoshi Hirayama , Masahiro Furutani , Tatsuo Shimizu , Kiyoshi Takayama , Tomoko Shimizu , Kazuya Suzuki
IPC分类号： C07K16/28 , A61K31/713 , A61K39/00
CPC分类号： C07K16/2866 , A61K31/713 , A61K2039/505 , C07K2317/70 , C07K2317/76
摘要： The present invention is novel anti-human-CC-motif-receptor-7 (anti-human-CCR7) antibodies useful for treating tissue fibrosis or cancer, and pharmaceutical compositions containing the anti-human-CCR7 antibodies. The invention includes an anti-human-CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77. The invention also includes an anti-human-CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. Preferably, the antibody has an activity of interfering with a CCR7-dependent intracellular signal transduction mechanism caused by CCR7 ligand stimulation.
摘要翻译： 本发明是可用于治疗组织纤维化或癌症的新型抗人CC-基质受体-7（抗人CCR7）抗体，以及含有抗人CCR7抗体的药物组合物。 本发明包括与人CCR7的细胞外结构域特异性结合的抗人CCR7抗体，其具有含有SEQ ID NO：7，SEQ ID NO：17，SEQ ID NO：27所示氨基酸序列的重链CDR3， SEQ ID NO：37，SEQ ID NO：47，SEQ ID NO：57，SEQ ID NO：67或SEQ ID NO：77.本发明还包括具有重链CDR 1-3的抗人CCR7抗体， 含有由SEQ ID NO：5-10，15-20,25-30,35-40,45-50,55-60,65-70或75-80表示的氨基酸序列的轻链CDR1-3。 优选地，抗体具有干扰由CCR7配体刺激引起的CCR7依赖性细胞内信号转导机制的活性。
-
公开(公告)号：US20130195869A1
公开(公告)日：2013-08-01
申请号：US13876265
申请日：2011-09-27
申请人： Naoki Nishiguchi , Akiyoshi Hirayama , Masahiro Furutani , Tatsuo Shimizu , Kiyoshi Takayama , Tomoko Shimizu , Kazuya Suzuki
发明人： Naoki Nishiguchi , Akiyoshi Hirayama , Masahiro Furutani , Tatsuo Shimizu , Kiyoshi Takayama , Tomoko Shimizu , Kazuya Suzuki
IPC分类号： C07K16/28
CPC分类号： C07K16/2866 , A61K31/713 , A61K2039/505 , C07K2317/70 , C07K2317/76
摘要： An object of the present invention is to provide a novel anti-human CCR7 antibody useful as a therapeutic agent for tissue fibrosis or cancer, and a pharmaceutical composition containing the anti-human CCR7 antibody, and the like. An anti-human CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77 is provided. Also provided is an anti-human CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. Preferably, the antibody has an activity of interfering with a CCR7-dependent intracellular signal transduction mechanism caused by CCR7 ligand stimulation. The anti-human CCR7 antibody of the present invention may be used as an active ingredient of a therapeutic agent for tissue fibrosis or cancer.
-
公开(公告)号：US20120196282A1
公开(公告)日：2012-08-02
申请号：US13015871
申请日：2011-01-28
CPC分类号： G01N33/502 , C12Q1/6876 , C12Q2600/136 , C12Q2600/158 , G01N33/74 , G01N2333/495
摘要： A method of regenerating an elastic fiber according in the present invention is characterized in that the method comprises bringing an elastic fiber regenerating agent containing LTBP-4 into contact with a cell having the fiber regenerating ability. Preferably, the elastic fiber regenerating agent further contains DANCE and/or LTBP-4 expression potentiating factor. According to the present invention, the elastic fiber regenerating ability is further enhanced than so far.
摘要翻译： 根据本发明的再生弹性纤维的方法的特征在于，该方法包括使含有LTBP-4的弹性纤维再生剂与具有纤维再生能力的电池接触。 优选地，弹性纤维再生剂还含有DANCE和/或LTBP-4表达增强因子。 根据本发明，弹性纤维再生能力比迄今为止进一步提高。
-
6.发明申请INHIBITOR OF CASEIN KINASE 1DELTA AND CASEIN KINASE 1EPSILON 有权CASEIN KINASE 1DELTA和CASEIN KINASE 1EPSILON的抑制剂公开(公告)号：US20110294857A1
公开(公告)日：2011-12-01
申请号：US13201309
申请日：2009-12-28
申请人： Masako Okamoto , Kiyoshi Takayama
发明人： Masako Okamoto , Kiyoshi Takayama
IPC分类号： A61K31/422 , A61P35/00 , A61P43/00 , A61P25/28 , A61K31/4439 , A61K31/433
CPC分类号： C07D413/04 , A61K31/422 , A61K31/433 , A61K31/4439 , C07D263/18 , C07D413/06 , C07D413/14 , C07D417/14
摘要： There is provided an inhibitor that inhibits casein kinase 1δ and casein kinase 1ε, and thus, there is also provided a pharmaceutical agent useful for the treatment and/or prevention of a disease, with the pathological condition of which the mechanism of activation of casein kinase 1δ or casein kinase 1ε is associated. Particularly, the above-described inhibitor is used to provide a pharmaceutical agent useful for the treatment of circadian rhythm disorder (including sleep disorder), central neurodegenerative disease, and cancer.An inhibitor of casein kinase 1δ and casein kinase 1ε, which comprises, as an active ingredient, an oxazolone derivative represented by the following general formula (1), a salt thereof, a solvate thereof, or a hydrate thereof: [wherein, in the formula (1), each of R1 and R2 independently represents any one of a substituted or unsubstituted 6-membered or 5-membered heterocyclic group optionally having a condensed ring, a substituted or unsubstituted aromatic hydrocarbon group optionally having a condensed ring, and a substituted or unsubstituted aromatic hydrocarbon lower alkyl group or aromatic hydrocarbon lower alkenyl group optionally having a condensed ring.]
摘要翻译： 提供了抑制酪蛋白激酶1δ和酪蛋白激酶1的抑制剂，因此，还提供了可用于治疗和/或预防疾病的药剂，其病理状况是酪蛋白的活化机制 激酶1δ或酪蛋白激酶1＆egr; 已关联的。 特别地，上述抑制剂用于提供可用于治疗昼夜节律紊乱（包括睡眠障碍），中枢神经变性疾病和癌症的药剂。 酪蛋白激酶1δ和酪蛋白激酶1抑制剂，其包含作为活性成分的由以下通式（1）表示的恶唑酮衍生物，其盐，其溶剂化物或其水合物：[其中，在 式（1）中，R 1和R 2各自独立地表示任选具有稠环的取代或未取代的6元或5元杂环基，任选具有稠环的取代或未取代的芳香族烃基， 取代或未取代的芳烃低级烷基或任选具有稠环的芳烃低级链烯基。
-
公开(公告)号：US08710231B2
公开(公告)日：2014-04-29
申请号：US13816180
申请日：2011-08-08
申请人： Masako Okamoto , Kiyoshi Takayama
发明人： Masako Okamoto , Kiyoshi Takayama
IPC分类号： C07D413/00 , C07D419/00 , C07D409/00 , C07D411/00 , A61K31/44 , A01N43/40
CPC分类号： A61K31/4439 , C07D413/14
摘要： There is provided a novel oxazolone derivative having inhibitory activity against casein kinase 1δ and casein kinase 1ε. In addition, the present inhibitor inhibits casein kinase 1δ and casein kinase 1ε, and thus there is also provided a pharmaceutical agent useful for the treatment and/or prevention of diseases, with the pathological conditions of which the activation mechanism of casein kinase 1δ or casein kinase 1ε is associated. There is further provided a pharmaceutical agent useful for the treatment of, particularly, circadian rhythm disorder (including sleep disorder), central neurodegenerative disease, and cancer. An inhibitor of casein kinase 1δ and casein kinase 1ε comprising, as an active ingredient, an oxazolone derivative represented by the following general formula (1), a salt thereof, a solvate thereof, or a hydrate thereof: wherein X represents a halogen atom which is fluorine, chlorine, bromine or iodine.
摘要翻译： 提供了一种对酪蛋白激酶1δ和酪蛋白激酶1具有抑制活性的新型恶唑酮衍生物。 此外，本发明的抑制剂抑制酪蛋白激酶1δ和酪蛋白激酶1和egr，因此还提供了可用于治疗和/或预防疾病的药剂，其病理条件是酪蛋白激酶1δ或 酪蛋白激酶1 已关联的。 还提供了用于治疗，特别是昼夜节律紊乱（包括睡眠障碍），中枢神经变性疾病和癌症的药剂。 酪蛋白激酶1δ和酪蛋白激酶1的抑制剂 作为活性成分，含有下述通式（1）表示的恶唑酮衍生物，其盐，溶剂化物或其水合物：其中，X表示氟，氯，溴或碘的卤素原子。
-
公开(公告)号：US20070172957A1
公开(公告)日：2007-07-26
申请号：US11505929
申请日：2006-08-18
IPC分类号： G01N33/92
CPC分类号： G01N33/5023 , G01N33/88 , G01N2500/00 , G01N2800/26
摘要： The invention relates to the screening and selection of macrolide compounds for use as anti-inflammatory agents. The screening and selection of anti-inflammatory macrolides is based on the differential expression of one or more genes involved in the inflammatory process.
摘要翻译： 本发明涉及用作抗炎剂的大环内酯类化合物的筛选和选择。 抗炎大环内酯类的筛选和选择是基于参与炎症过程的一种或多种基因的差异表达。
-
9.发明授权公开(公告)号：US06723521B1
公开(公告)日：2004-04-20
申请号：US09720655
申请日：2001-02-28
IPC分类号： G01N3353
CPC分类号： C07K14/47
摘要： A gene hucep-8 coding for a novel protein HUCEP-8 having sugar-transporting activity can be obtained by cloning from a cDNA library derived from human cerebral cortex.
摘要翻译： 编码具有糖转运活性的新型蛋白质HUCEP-8的基因hucep-8可通过从源自人大脑皮质的cDNA文库克隆得到。
-
公开(公告)号：US09018238B2
公开(公告)日：2015-04-28
申请号：US13201309
申请日：2009-12-28
申请人： Masako Okamoto , Kiyoshi Takayama
发明人： Masako Okamoto , Kiyoshi Takayama
IPC分类号： A61K31/422 , A61K31/433 , A61K31/4439 , C07D413/06 , C07D413/14 , C07D417/14 , C07D413/04 , C07D263/18
CPC分类号： C07D413/04 , A61K31/422 , A61K31/433 , A61K31/4439 , C07D263/18 , C07D413/06 , C07D413/14 , C07D417/14
摘要： There is provided an inhibitor that inhibits casein kinase 1δ and casein kinase 1ε, and thus, there is also provided a pharmaceutical agent useful for the treatment and/or prevention of a disease, with the pathological condition of which the mechanism of activation of casein kinase 1δ or casein kinase 1ε is associated. Particularly, the above-described inhibitor is used to provide a pharmaceutical agent useful for the treatment of circadian rhythm disorder (including sleep disorder), central neurodegenerative disease, and cancer.An inhibitor of casein kinase 1δ and casein kinase 1ε, which comprises, as an active ingredient, an oxazolone derivative represented by the following general formula (1), a salt thereof, a solvate thereof, or a hydrate thereof: [wherein, in the formula (1), each of R1 and R2 independently represents any one of a substituted or unsubstituted 6-membered or 5-membered heterocyclic group optionally having a condensed ring, a substituted or unsubstituted aromatic hydrocarbon group optionally having a condensed ring, and a substituted or unsubstituted aromatic hydrocarbon lower alkyl group or aromatic hydrocarbon lower alkenyl group optionally having a condensed ring.]
摘要翻译： 提供了抑制酪蛋白激酶1δ和酪蛋白激酶1的抑制剂，因此，还提供了可用于治疗和/或预防疾病的药剂，其病理状况是酪蛋白的活化机制 激酶1δ或酪蛋白激酶1＆egr; 已关联的。 特别地，上述抑制剂用于提供可用于治疗昼夜节律紊乱（包括睡眠障碍），中枢神经变性疾病和癌症的药剂。 酪蛋白激酶1δ和酪蛋白激酶1抑制剂，其包含作为活性成分的由以下通式（1）表示的恶唑酮衍生物，其盐，其溶剂化物或其水合物：[其中，在 式（1）中，R 1和R 2各自独立地表示任选具有稠环的取代或未取代的6元或5元杂环基，任选具有稠环的取代或未取代的芳香族烃基， 取代或未取代的芳烃低级烷基或任选具有稠环的芳烃低级链烯基。
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.028 秒)